The Management and Treatment of Hypertension

Clinical cornerstone Pub Date : 2009-01-01 Epub Date: 2009-05-01 DOI:10.1016/S1098-3597(09)60016-8
F. Wilford Germino MD
{"title":"The Management and Treatment of Hypertension","authors":"F. Wilford Germino MD","doi":"10.1016/S1098-3597(09)60016-8","DOIUrl":null,"url":null,"abstract":"<div><p><span><span><span><span>High blood pressure (HBP) is one of the most prevalent conditions seen today by clinicians, affecting an estimated 73 million–or 1 in 3—adult Americans, only one third of whom have achieved control of their hypertension (HBP). Central to the management of this pervasive medical condition are the issues of accurate diagnosis and maintaining control through appropriate treatment. Accurate diagnosis depends primarily on reliable measurement. Over the years, it has become increasingly recognized that blood pressure (BP) measurement occurring in clinical settings produces far less accurate and reliable readings than do other methods, notably 24-hour </span>ambulatory BP monitoring and home BP measurement. Beyond technique, there are additional challenges to obtaining accurate readings, including emotional factors that produce either falsely elevated or lowered results, having the potential to mislead the clinician. The need to overcome obstacles to proper diagnosis and determine effective treatments has reached heightened urgency, especially for patients with compelling comorbidities such as diabetes, </span>renal disease<span><span>, congestive heart failure, and other cardiovascular diseases. The continuing evolution of the management of HBP is reflected in updated guidelines from the American Heart Association and evidence-based information stemming from recent studies and </span>randomized clinical trials. The appropriate selection of </span></span>antihypertensive agents, at the proper doses, is a complex issue requiring greater understanding of our pharmacologic options. The contributions of some of the more recent and salient studies and trials are mentioned here, although there is no attempt in this brief review to match </span>drug<span><span> classes with compelling indications. The trials discussed involve such pharmacologic treatments as diuretic therapy<span><span>, α-blockers, conventional β-blockers, calcium channel blockers, angiotensin-converting enzyme inhibitors, and </span>angiotensin receptor blockers. Trial outcomes shed light on the relative benefits and drawbacks of these agents, often within the context of various </span></span>patient characteristics such as age, comorbidities, and risk status. Successful management of HBP is a multi-faceted and ongoing endeavor, in which developing knowledge constantly tempered by new questions moves us toward the goal of improving the lives of our patients.</span></p></div>","PeriodicalId":80265,"journal":{"name":"Clinical cornerstone","volume":"9 ","pages":"Pages S27-S33"},"PeriodicalIF":0.0000,"publicationDate":"2009-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/S1098-3597(09)60016-8","citationCount":"27","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical cornerstone","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1098359709600168","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2009/5/1 0:00:00","PubModel":"Epub","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 27

Abstract

High blood pressure (HBP) is one of the most prevalent conditions seen today by clinicians, affecting an estimated 73 million–or 1 in 3—adult Americans, only one third of whom have achieved control of their hypertension (HBP). Central to the management of this pervasive medical condition are the issues of accurate diagnosis and maintaining control through appropriate treatment. Accurate diagnosis depends primarily on reliable measurement. Over the years, it has become increasingly recognized that blood pressure (BP) measurement occurring in clinical settings produces far less accurate and reliable readings than do other methods, notably 24-hour ambulatory BP monitoring and home BP measurement. Beyond technique, there are additional challenges to obtaining accurate readings, including emotional factors that produce either falsely elevated or lowered results, having the potential to mislead the clinician. The need to overcome obstacles to proper diagnosis and determine effective treatments has reached heightened urgency, especially for patients with compelling comorbidities such as diabetes, renal disease, congestive heart failure, and other cardiovascular diseases. The continuing evolution of the management of HBP is reflected in updated guidelines from the American Heart Association and evidence-based information stemming from recent studies and randomized clinical trials. The appropriate selection of antihypertensive agents, at the proper doses, is a complex issue requiring greater understanding of our pharmacologic options. The contributions of some of the more recent and salient studies and trials are mentioned here, although there is no attempt in this brief review to match drug classes with compelling indications. The trials discussed involve such pharmacologic treatments as diuretic therapy, α-blockers, conventional β-blockers, calcium channel blockers, angiotensin-converting enzyme inhibitors, and angiotensin receptor blockers. Trial outcomes shed light on the relative benefits and drawbacks of these agents, often within the context of various patient characteristics such as age, comorbidities, and risk status. Successful management of HBP is a multi-faceted and ongoing endeavor, in which developing knowledge constantly tempered by new questions moves us toward the goal of improving the lives of our patients.

高血压的管理和治疗
高血压(HBP)是当今临床医生看到的最普遍的疾病之一,影响着大约7300万(即三分之一的美国成年人),其中只有三分之一的人控制了他们的高血压(HBP)。管理这种普遍疾病的核心问题是准确诊断和通过适当治疗保持控制。准确的诊断主要依赖于可靠的测量。多年来,人们越来越认识到,在临床环境中测量血压(BP)产生的读数远不如其他方法准确和可靠,特别是24小时动态血压监测和家庭血压测量。除了技术之外,获得准确的读数还有其他的挑战,包括情绪因素会产生错误的升高或降低的结果,有可能误导临床医生。克服障碍进行正确诊断和确定有效治疗的需要已经变得更加紧迫,特别是对于患有糖尿病、肾病、充血性心力衰竭和其他心血管疾病等严重合并症的患者。美国心脏协会的最新指南以及来自近期研究和随机临床试验的循证信息反映了HBP管理的不断发展。选择合适剂量的降压药是一个复杂的问题,需要对我们的药理学选择有更深入的了解。尽管在这篇简短的综述中并没有试图将药物类别与令人信服的适应症相匹配,但在这里提到了一些最近和突出的研究和试验的贡献。所讨论的试验包括利尿剂治疗、α-阻滞剂、常规β-阻滞剂、钙通道阻滞剂、血管紧张素转换酶抑制剂和血管紧张素受体阻滞剂等药物治疗。试验结果揭示了这些药物的相对优点和缺点,通常是在不同患者特征的背景下,如年龄、合并症和风险状态。成功的HBP管理是一个多方面和持续的努力,在这个过程中,不断发展的知识受到新问题的考验,使我们朝着改善患者生活的目标前进。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信
小红书